Some GLP-1 users have reported that semaglutide affects menstrual cycles and tirzepatide affects periods , which can further impact iron status through changes in blood loss
She has served on scientific advisory panels and speaker bureaus for Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and other companies
With the FDA changing their view on peptide therapy in 2023, the medical community was motivated to continue to offer regenerative peptides since they fix the actual issues in the body, not just mask the symptoms
Individual components of KLOW have varying regulatory statuses GHK-Cu, for example, is FDA-approved for topical cosmetic use but not for injection
Some people stop taking GLP-1 medications and maintain their results